Addus HomeCare (ADUS) has just put fresh numbers on the table for Q1 2026, coming off a Q4 2025 result that featured US$373.1 million in revenue and basic EPS of US$1.61, supported by trailing 12 month EPS of US$5.31 on revenue of about US$1.4 billion. Over recent quarters the company has seen revenue move from US$289.8 million in Q3 2024 to US$373.1 million in Q4 2025. Quarterly basic EPS has ranged from US$1.07 to US$1.61 over the same period, setting up Q1 2026 against a backdrop of 30.3% earnings growth and a 6.7% trailing net margin that puts profitability in clear focus for investors.

See our full analysis for Addus HomeCare.

With the headline figures on the board, the next step is to see how these results line up with the prevailing narratives about Addus HomeCare, from its growth outlook to the balance between earnings momentum and more moderate forward expectations.

30.3% earnings growth fuels bullish case

• Trailing 12 month net income is US$95.9 million on US$1.4b of revenue, which lines up with 30.3% earnings growth and a 6.7% net margin compared with 6.4% a year earlier.
• Supporters of the bullish view point to this earnings profile as a base for faster growth, yet the current data creates some tension with that story:
  • Bullish assumptions look for revenue to grow 12.0% a year and earnings to reach US$145.3 million by 2028, while the latest trailing revenue is US$1.4b and earnings are US$95.9 million, so the step up from today is meaningful.
  • Bulls also assume margins could reach 8.1% versus the current 6.7% net margin, so the recent margin level supports quality, but the extra margin expansion they expect is not visible in the historical figures yet.

Bulls argue that recent margin resilience and earnings growth could be the starting point for a bigger profitability shift, and that is exactly what their longer term narrative sets out to test in detail. 🐂 Addus HomeCare Bull Case

Valuation gap vs 136.62 analyst target

• With the share price at US$98.44, the referenced analyst price target of US$136.62 and a DCF fair value of about US$185.91 both sit well above where the stock is trading. The trailing P/E of 18.8x is below the cited US healthcare industry average of 24.9x and peer average of 23x.
• Analysts who take a more balanced stance see both support and friction for a re rating when set against these numbers:
  • The combination of 30.3% trailing earnings growth and a lower than industry P/E ratio lines up with the idea that the current price does not fully reflect recent profitability, which fits with an analyst target above today’s level.
  • At the same time, the dataset cites forward earnings growth of about 6.8% a year and revenue growth of 4.4% a year, which are below the referenced broader US market, so the more modest outlook helps explain why the consensus target is well under the DCF fair value even though it is higher than the present share price.

6.7% margin tested by bearish policy worries

• The 6.7% trailing net margin, compared with 6.4% a year earlier, sits alongside forecasts for earnings growth of about 6.8% per year and revenue growth of about 4.4% per year, which the dataset notes are below the broader US market growth rates it cites.
• Critics who lean bearish focus on how sensitive that margin could be to policy and cost trends, and the current figures both support and challenge those worries:
  • Bears highlight risks from potential cuts or slower growth in Medicaid and Medicare reimbursement and from wage inflation, yet the trailing 6.7% margin and 30.3% earnings growth show that, so far, reimbursement levels and costs have still allowed earnings to grow.
  • However, the more moderate forward growth expectations of 6.8% earnings and 4.4% revenue growth per year leave limited room if reimbursement pressure or higher labor costs emerge, which fits with the idea that future policy or wage changes could have a more visible impact than the trailing numbers suggest.

Skeptics warn that current margins leave only a modest buffer if reimbursement or labor costs move against the company, and that tension is at the heart of the cautious narrative. 🐻 Addus HomeCare Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Addus HomeCare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bullish and cautious views feels balanced, now is a good time to look at the numbers yourself and stress test the story. To see what optimism is anchored to in the data, review the 4 key rewards.

See What Else Is Out There

Forward revenue growth of 4.4% and earnings growth of 6.8% a year, both cited as below the broader US market, highlight growth limitations.

If slower projected growth is making you hesitate, use the screener containing 25 high quality undiscovered gems to quickly spot companies where stronger forecasts are already supported by solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.